VAERS Data Reveal Serious Adverse Event Reports in Babies After mRNA COVID Shots
On June 15, 2022, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) advised the FDA to grant an Emergency Use Authorization (EUA) for Moderna/NIAID and Pfizer/BioNTech’s mRNA COVID-19 biologics be given to infants and children under age five and as young as six months old. With […]
Research Confirms Menstrual Cycle Bleeding Changes After COVID Shot
Last week, University of Illinois researchers published a study funded by the National Institutes of Health (NIH) in the journal Science Advances on menstrual cycle bleeding changes after COVID shots. The study featured a web-based survey of almost 40,000 individuals and found 42 percent of those who were menstruating reported unexpected heavy bleeding after receiving […]
FDA Grants EUA for Novavax’s COVID Vaccine
Opinion | On July 13, 2022, the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) to Novavax to distribute its experimental two-dose NVX-CoV2373 (also known as “Nuvaxovid” and “Covovax”) COVID-19 vaccine for use by adults. The decision was expected, given the favorable recommendation by the FDA’s Vaccines and Related Biological Products Advisory […]
‘COVID-19 Rebound’ May Be Worse Than Initial COVID Illness
On May 24, 2022, the U.S. Centers for Disease Control and Prevention (CDC) issued a health advisory to health care providers, public health departments and the general public regarding Pfizer’s antiviral drug Paxlovid, designed to treat symptoms of COVID-19. The advisory warns that some people who take Paxlovid may experience a recurrence of COVID symptoms […]
U.S. Becomes First Country to Give mRNA COVID Vaccine to Babies
On June 15, 2022 the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) unanimously advised the FDA staff to grant Moderna and Pfizer/BioNTech an Emergency Use Authorization (EUA) amendment to allow their mRNA COVID vaccines to be given to children under age five and as young as […]
FDA Panel Recommends EUA for Novavax COVID-19 Vaccine
Despite concerns about the risk of developing myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining of the heart) following vaccination with Novavax’s experimental NVX-CoV2373 (also known as “Nuvaxovid” and “Covovax”) COVID-19 vaccine, the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted on June 6, […]